Anti-VWF D'D3 single-domain antibodies and methods of use
US10626186B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 25, 2017 |
| Grant date | Apr 21, 2020 |
| Priority date | — |
| Expiry date | Jan 25, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D′D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also rotates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D′D3 domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.